DBV Technologies | DBVT - 债务



金融业
股票价格
USD
资产
USD 110.5M
现金及等价物
USD 69.84M
流动资产
USD 88.88M
流动负债
USD 49.49M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 52.85M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 758.8M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


债务 更改 日
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amarin USD 0 0 2025-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
DBV Technologies USD 8.59M 295K 2025-09
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Galectin Therapeutics USD 71.74M 10.6M 2023-12
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Incyte USD 40.41M 855K 2025-12
Insmed USD 727.89M 163.33M 2025-12
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
PTC Therapeutics USD 2.71B 2.42B 2025-12
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
United Therapeutics USD 200M 100M 2025-03